A股異動 | 微芯生物(688321.SH)大漲逾8% 西格列他鈉片獲得臨牀試驗通知書
格隆匯6月2日丨微芯生物(688321.SH)大漲逾8%,報41.46元,高見43.05元創約一年半新高,總市值170億元。微芯生物本週一宣佈,公司全資子公司成都微芯藥業有限公司近日收到國家藥監局簽發的有關西格列他鈉片的《臨牀試驗通知書》。西格列他鈉是全球首個完成III期臨牀試驗的PPAR全激動劑,單藥用於治療飲食、運動控制不佳的2型糖尿病的NDA(新藥申請)已於2019年9月被國家藥監局受理,現場生產核查已經順利結束,目前正在行政審評審批中。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.